USPTO 2015–2025 USPTO PatentsView US Corporation

Labyrinth Holdings, LLC

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Labyrinth ranks #48,277 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#48,277
of 49,997 US assignees by volume
27th percentile
by Innovation Score (28.4/100)
12.8
avg claims per patent
-67%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R48277 · US Corporation #48,277 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #48,277/49,997
  • PHOTO-FINISH La Jolla Pharmaceuti…
  • CPC-NARROW A61P · 5 areas
  • INNOV-THIN 28.4/100
  • CLAIMS-RICH 12.8 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DROP -67% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: La Jolla Pharmaceuticals Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Labyrinth

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Labyrinth's Innovation Score is 28.4/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Labyrinth's grants concentrate

Labyrinth Holdings, LLC is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2017. By volume, Labyrinth sits between La Jolla Pharmaceuticals Company and Laminar Medica Limited.

Labyrinth's three-year grant acceleration

Labyrinth Holdings, LLC shows 1 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Labyrinth's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Labyrinth holds 5 patents at rank #48,395, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Labyrinth

By rank, the assignees closest to #48,395 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Labyrinth's primary technology class.

Labyrinth's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2017201820242025 1
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
Labyrinth Holdings, LLC patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 20.0%
2018 2 40.0%
2024 1 20.0%
2025partial year 1 20.0%

Where it ranks

Overall rank by patents

#48,277

of 49,997 tracked assignees

Innovation Score

28.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Labyrinth Holdings, LLC's patent record in context - here's where to go next.

  • Labyrinth Holdings, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #48,277 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Labyrinth Holdings, LLC against La Jolla Pharmaceuticals Company, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.